VSTM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Verastem Inc (VSTM) is not a strong buy at the moment for a beginner investor with a long-term horizon. While analysts have a positive outlook with high price targets and hedge funds are showing increased interest, the technical indicators are bearish, financial performance is weak, and there are no recent news catalysts. Given the user's impatience and unwillingness to wait for optimal entry points, it is better to hold off on investing in VSTM at this time.
The technical indicators for VSTM are bearish. The MACD histogram is negative and contracting, the RSI is neutral at 41.792, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels suggest limited upward momentum with a pivot at 5.443 and resistance at 5.878.
Analysts have consistently rated the stock as a Buy with price targets ranging from $14 to $19, citing the company's pipeline programs and commercial launch momentum. Hedge funds have significantly increased their buying activity, up 1120.13% over the last quarter.
The financial performance in Q4 2025 was weak, with a 49.01% YoY drop in net income, a 70.45% YoY drop in EPS, and a decline in gross margin by 16.49%. Additionally, there are no recent news catalysts or congress trading data to support a positive sentiment.
In Q4 2025, revenue remained flat at $17.535 million, but net income dropped significantly to -$32.916 million (-49.01% YoY). EPS also declined sharply to -0.39 (-70.45% YoY), and gross margin decreased to 83.51% (-16.49% YoY). The financials indicate a challenging period for the company.
Analysts have a positive outlook on VSTM, with multiple Buy ratings and price targets ranging from $14 to $19. They highlight the company's undervaluation, strong pipeline programs, and commercial launch momentum in low-grade serous ovarian cancer.
